Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Change in Accured Expenses (2019 - 2025)

Historic Change in Accured Expenses for IDEAYA Biosciences (IDYA) over the last 7 years, with Q4 2025 value amounting to -$4.8 million.

  • IDEAYA Biosciences' Change in Accured Expenses fell 31103.78% to -$4.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $10.4 million, marking a year-over-year decrease of 340.0%. This contributed to the annual value of $10.4 million for FY2025, which is 340.0% down from last year.
  • As of Q4 2025, IDEAYA Biosciences' Change in Accured Expenses stood at -$4.8 million, which was down 31103.78% from $7.5 million recorded in Q3 2025.
  • IDEAYA Biosciences' Change in Accured Expenses' 5-year high stood at $7.5 million during Q3 2025, with a 5-year trough of -$4.8 million in Q4 2025.
  • Over the past 5 years, IDEAYA Biosciences' median Change in Accured Expenses value was $2.1 million (recorded in 2021), while the average stood at $1.6 million.
  • Over the last 5 years, IDEAYA Biosciences' Change in Accured Expenses had its largest YoY gain of 66811.15% in 2023, and its largest YoY loss of 39928.57% in 2023.
  • IDEAYA Biosciences' Change in Accured Expenses (Quarter) stood at $476000.0 in 2021, then plummeted by 32.14% to $323000.0 in 2022, then skyrocketed by 668.11% to $2.5 million in 2023, then decreased by 8.34% to $2.3 million in 2024, then tumbled by 311.04% to -$4.8 million in 2025.
  • Its Change in Accured Expenses was -$4.8 million in Q4 2025, compared to $7.5 million in Q3 2025 and $4.8 million in Q2 2025.